4,113 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Clare Market Investments LLC

Clare Market Investments LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,113 shares of the company's stock, valued at approximately $670,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Vista Investment Partners II LLC acquired a new position in Zoetis in the 4th quarter worth about $1,879,000. Morton Community Bank grew its position in Zoetis by 4.4% in the fourth quarter. Morton Community Bank now owns 16,694 shares of the company's stock worth $2,720,000 after acquiring an additional 705 shares in the last quarter. Independent Advisor Alliance increased its stake in shares of Zoetis by 25.7% during the 4th quarter. Independent Advisor Alliance now owns 7,211 shares of the company's stock worth $1,175,000 after purchasing an additional 1,475 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Zoetis by 4.7% in the 4th quarter. Daiwa Securities Group Inc. now owns 75,874 shares of the company's stock valued at $12,362,000 after purchasing an additional 3,421 shares during the last quarter. Finally, Moran Wealth Management LLC increased its position in Zoetis by 2.1% during the fourth quarter. Moran Wealth Management LLC now owns 66,596 shares of the company's stock worth $10,850,000 after buying an additional 1,366 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS traded down $1.65 on Thursday, reaching $160.03. 2,744,683 shares of the stock traded hands, compared to its average volume of 2,560,225. The stock's 50-day moving average price is $166.86 and its 200-day moving average price is $176.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market cap of $71.66 billion, a price-to-earnings ratio of 29.26, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.25%. Zoetis's dividend payout ratio is currently 36.56%.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 over the last three months. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ZTS shares. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target on the stock. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of "Buy" and a consensus target price of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.